Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

pembrolizumab 111Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 68Cisplatin 67Biopsy 57Nivolumab 56Radiotherapy 51Cyclophosphamide 50Paclitaxel 48durvalumab 38Radiation 38Gemcitabine 37olaparib 32Rituximab 32Etoposide 32Dexamethasone 32Doxorubicin 30Docetaxel 30atezolizumab 29Lenalidomide 27Ipilimumab 27Taxes 26Pemetrexed 26Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Radiotherapy, Intensity-Modulated 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ibritumomab tiuxetan × 90 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡